Team IDs weakness in anthrax bacteria
The researchers found that nitric oxide (NO) is a critical part of Bacillus anthracis's defense against the immune response launched by cells infected with the bacterium. Anthrax bacteria that cannot produce NO succumb to the immune system's attack.
Stephen Lippard, the Arthur Amos Noyes Professor of Chemistry at MIT and an author of a paper on the work, said antibiotics developed to capitalize on this vulnerability could be effective against other bacteria that employ the same defense system. Those bacteria include Staphylococcus aureus, which commonly causes infections in hospitals and can be extremely drug-resistant.
The paper appears in the Jan. 21 online edition of the Proceedings of the National Academy of Sciences
Anthrax occurs naturally around the world and can infect all warm-blooded animals including humans. Treatment usually includes large doses of intravenous and oral antibiotics, but the disease can often be fatal-especially if treatment is not started right away.
In the human immune system, specialized cells called macrophages are the first line of defense against anthrax infection. Macrophages engulf the bacteria and bombard them with reactive oxygen and nitrogen species, which create chemical reactions toxic to the bacteria.
The research team found that NO produced by the bacteria preemptively defends against attack by reactive oxygen species produced by the macrophages soon after infection. Twelve hours later, when the macrophages release NO to join in the attack, it is too late-by then the bacteria have taken over and eventually destroy the macrophages.
When the gene for the enzyme that synthesizes NO is knocked out in the bacteria, they cannot defend against early attack by the macrophages, which can then survive the infection.
“With the aid of an intracellular probe developed in our laboratory, which fluoresces in the presence of NO, our collaborators Evgeny Nudler and his group discovered a completely new target for the next generation of antibiotics,” said Lippard.
With this knowledge in hand, the researchers are now using the fluorescent probe to screen libraries of chemicals for compounds that could potentially interfere with the bacterium's ability to synthesize NO, said Lippard. Such compounds could eventually be developed into new antibiotics.
Lead author of the paper is Konstantin Shatalin of the New York University School of Medicine. The research was funded by the National Institutes of Health and the National Science Foundation.
All news from this category: Life Sciences
Articles and reports from the Life Sciences area deal with applied and basic research into modern biology, chemistry and human medicine.
Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.
Rare quadruple-helix DNA found in living human cells with glowing probes
New probes allow scientists to see four-stranded DNA interacting with molecules inside living human cells, unravelling its role in cellular processes. DNA usually forms the classic double helix shape of…
A rift in the retina may help repair the optic nerve
In experiments in mouse tissues and human cells, Johns Hopkins Medicine researchers say they have found that removing a membrane that lines the back of the eye may improve the…